SEP 0 9 2005 W

1642 PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re ap	plication of:)	
\$	Saori KITAO, et al.) Group Art No. 1642	
Serial N	To.: 09/889,325) Examiner: C. Yaen	
Filed: Ja	anuary 19, 2000) Docket No: 004276.000	03
,	GENE CAUSATIVE OF ROTHMUND- THOMSON SYNDROME AND GENE PRODUCT)))	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT C.F.R. § 1.97(d)

Commissioner of Patents c/o Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

Submitted herewith are (2) sheets of Form PTO-1449. A copy of each of the references listed therein is enclosed. It is respectfully requested that the Examiner make his/her consideration of this document formally of record.

This Information Disclosure Statement is filed pursuant to 37 C.F.R. § 1.97 (d). The undersigned certifies that all items of information contained in the Information Disclosure Statement were first cited in a communication from the examiner in a parent application dated and that this communication was issued on July 21, 2005, which is less than three months prior to the filing of this Information Disclosure Statement. To my knowledge, no item of information 190733 09889325

09/13/2005 HALI11 00000120 190733 0988932 01 FC:1806 180.00 DA contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The Commissioner is authorized to charge \$180.00 in accordance with C.F.R. § 1.17(p) to effect entry of this Information Disclosure Statement to Deposit Account 19-0733. Further, the Commissioner is authorized to charge any additional fees which may be required or credit any overpayment to our Deposit Account 19-0733.

Respectfully submitted,

Date: September 9, 2005

By:

Michelle L. Holmes-Son

Registration No. 47,660

Customer No. 22907 Banner & Witcoff, Ltd.

PTO/SB/08a (08-03)

001107.00454

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Attorney Docket Number

no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A Under the Pap ork Reduction Act of Complete if Known Application Number 09/889,325 INFORMATION DISCLOSURE Filing Date December 31, 2001 STATEMENT BY APPLICANT First Named Inventor Saori KITAO Art Unit 1642 (Use as many sheets as necessary) Examiner Name C. YAEN

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant			
Initials *	No.1	Number – Kind Code ² (if known)	MM-DD-YYYY	Once becamen	Passages or Relevant Figures Appear		
		US-6,335,435	01/01/2002	Shimamoto et al.			

Sheet

of

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)				T ⁶		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Cite the item (book, magazine, journal, serial, symp		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
		OVERBEEK, PA et al., "Transgenic Animal Technology: A Laboratory Handbook," Factors affecting transgenic animal production, pp. 96-98 (1994)				
		WALL, RJ. "Transgenic Livestock: Progress and Prospects for the Future," <i>Thenogenology</i> , Vol. 45, No. 1, pp. 57-68 (1996)				
		HOUDEBINE, L., "Production of pharmaceutical proteins from transgenic animals," <i>J. Biotech.</i> Vol. 34, No. 3, pp. 269-87 (1994)				
		KAPPEL CA et al., "Regulating gene expression in transgenic animals," Curr Opin Biotech, Vol. 3, No. 5, pp. 548-53 (1992)				
		CAMERON ER. ""Recent Advances in Transgenic Technology," Mol. Biotech, Vol. 7, No. 3, pp. 253-65 (1997)				
		NIEMAN II., "Transgenic farm animals get off the ground," <i>Transgenic Res.</i> ; Vol. 7, No. 1, pp. 73-5 (1998)				
		MULLINS JJ. and MULLINS, L. "Transgenesis in Nonmurine Species," <i>Hypertension</i> , Vol. 22, No. 4, pp. 630-3 (1993)				

Examiner	Date	
Signature	Considered	
	 ı	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known O P E			
		ON DIO		Application Number	09/889,325	1 kg	
	•		CLOSURE	Filing Date	December 31		
STATEMENT BY APPLICANT		First Named Inventor	Saori KITAO	SEP U 9 2005			
				Art Unit	1637	13 8	
(Use as many sheets as necessary)			necessary)	Examiner Name	C. YAEN	To Description	
Sheet	2	of	2	Attorney Docket Number	004276.0000	3	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		MULLINS, JJ. et al., "Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene," Nature, Vol. 344, No. 6266, pp. 541-4 (1990)	
		HAMMER, R. et al., "Spontaneous Inflammatory Disese in Transgenic Rats Expressing HLA-B27 and Human B2m: An Animal Model of HLA-BS&-Associated Human Disorders," <i>Cell</i> Vol. 63, pp. 1099-1112 (1990)	
		MULLINS, JJ, et al., "Expression of the DBA/2J Ren-2 gene in the adrenal gland of transgenic mice," <i>EMBO J</i> Vol. 8, No. 13, pp. 4065-4072 (1989)	
		TAUROG, JD. et al., "HLA-B27 in Inbred and Non-inbred Transgenic Mice," J. Immunol., Vol. 141, No. 11, pp. 4020-3 (1988)	
		MULLINS, L and MULLINS, JJ. "Perspective Series: Molecular Medicine in Genetically Engineered Animals," J. Clin. Invest., Vol. 98, No. 11, pp.S37-40 (1996)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.